| Bioactivity | Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML)[1]. |
| Target | KD: 0.3 nM (CD33, HL-60 cells), 5.1 nM (CD3, Human T cells) |
| Invitro | Vixtimotamab (TandAb T564; 24 h) 诱导 CD25 和 CD69, EC50 分别为 1 pM 和 2 pM[1]。Vixtimotamab (TandAb T564; 4 days) 诱导 PBMCs 中的 T 细胞增殖，EC50 为 3 pM[1]。Vixtimotamab (TandAb T564; 25 pM, 48 h) 显示对 HL-60 和 KG-1a 细胞的细胞毒性[1]。 Cell Cytotoxicity Assay[1] Cell Line: |
| In Vivo | Vixtimotamab (TandAb T564; 0.1-10 μg/mouse, i.v.; 5 days) 在预防性 HL-60 移植 NOD/scid 小鼠模型中显示剂量依赖性肿瘤生长延迟[1]。Vixtimotamab (TandAb T564; 50 μg/mouse/d, i.v.; 7 days) 在建立的 HL-60 移植 NOD/scid 小鼠模型中显著抑制肿瘤生长[1]。 Animal Model: |
| Name | Vixtimotamab |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Reusch U, et al. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia. Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. |